What it sells
Redefining the Standard of Care for Iron Deficiency Anemia
Business model breakdown
Trigger: what makes them buy now?
Oral iron causes GI side effects and IV iron has adverse effects and requires clinic infusion.
Workflow: what inputs become what output?
Self-administered transdermal iron patch (NistuFe, new molecular entity KYLK01) delivers iron directly into blood bypassing the GI tract, aiming to combine oral iron convenience with IV iron efficacy.
Economics: what it saves and how it charges
UnverifiedPre-commercial drug developer; value from Rx product approval and licensing; no revenue claims published.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2022 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.